2-165992006-C-G
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PS1PM1PM2PP2PP3_StrongPP5_Moderate
The NM_001165963.4(SCN1A):c.5269G>C(p.Gly1757Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin Lovd.
Frequency
Consequence
NM_001165963.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN1A | NM_001165963.4 | c.5269G>C | p.Gly1757Arg | missense_variant | 29/29 | ENST00000674923.1 | NP_001159435.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN1A | ENST00000674923.1 | c.5269G>C | p.Gly1757Arg | missense_variant | 29/29 | NM_001165963.4 | ENSP00000501589.1 | |||
SCN1A | ENST00000303395.9 | c.5269G>C | p.Gly1757Arg | missense_variant | 28/28 | 5 | ENSP00000303540.4 | |||
SCN1A | ENST00000375405.7 | c.5236G>C | p.Gly1746Arg | missense_variant | 26/26 | 5 | ENSP00000364554.3 | |||
SCN1A | ENST00000409050.1 | c.5185G>C | p.Gly1729Arg | missense_variant | 26/26 | 5 | ENSP00000386312.1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 21, 2017 | This variant has been observed in an individual with Dravet syndrome (Invitae). For these reasons, this variant has been classified as Pathogenic. This variant identified in the SCN1A gene is located in the transmembrane spanning D4-S6 region of the resulting protein (PMID: 25348405, 18804930), but it is unclear how this variant impacts the function of this protein. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SCN1A-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 1757 of the SCN1A protein (p.Gly1757Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. A different variant (c.5269G>A) giving rise to the same protein effect observed here (p.Gly1757Arg) has been reported to be de novo in two individuals affected with Dravet syndrome (PMID: 27781031, 27465585), indicating that this residue may be critical for protein function. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at